Mihaela Catalina Luca, A. Vata, A. Luca, Carmen Dorobat
Chronic hepatitis C is an important cause of morbidity and mortality due o hepatic disease. Material and method The retrospectively studied the evolution of 30 patients with chronic hepatitis C, treated in the Infectious Diseases Hospital of Iasi, with Peginterferon and Ribavirin for 48 weeks. Results 18 patients were treated with Peginterferon α2a and Ribavirin, and 12 with Peginterferon α2b and Ribavirin. Most of them (73.3%) were adults, aged between 30 and 50 years, with a sex ratio M/F – 13/17. Most of them had risk factors for the transmission of HCV: 28 of them suffered surgery and 2 of them had infected sexual partners. 3 patients didn’t achieve a rapid virusologic response and 6 patients were relapsers. All the other 70% of patients had a sustained virologic response. The side effects were present in all patients, with a moderate intensity. Conclusion The success (SVR) rate of antiviral therapy was higher than expected (especially for genotype 1 HCV). The patients with a viral relapse could be soon treated with the new protease inhibitors and hope for a cure.
RJOR.RO utilizeaza fisiere de tip cookie pentru a personaliza si imbunatati experienta ta pe Website-ul nostru. Te informam ca ne-am actualizat politicile pentru a integra in acestea si in activitatea curenta a adre.ro cele mai recente modificari propuse de Regulamentul (UE) 2016/679 privind protectia persoanelor fizice in ceea ce priveste prelucrarea datelor cu caracter personal si privind libera circulatie a acestor date. inainte de a continua navigarea pe Website-ul nostru te rugam sa aloci timpul necesar pentru a citi si intelege continutul Politicii de Cookie. Prin continuarea navigarii pe Website-ul nostru confirmi acceptarea utilizarii fisierelor de tip cookie conform Politicii de Cookie. Nu uita totusi ca poti modifica in orice moment setarile acestor fisiere cookie urmand instructiunile din Politica de Cookie
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.